Sleep Impairment in Subjects at Risk of Developing Alzheimer's Disease

Condition(s) studied

Investigational drug(s) / intervention(s)

Polysomnography: Polysomnography will be performed for 24 hours at inclusion and 24 months

Neuropsychological assessment: A full neuropsychological assessment will be performed at inclusion, 12 and 24 months

Questionnaires on sleep and behavioural problems: Questionnaires on sleep and behavioural problems

Actimetrics: Measurement of actimetrics for 14 days at inclusion and at 24 months

Biomarker assay: Determination of the biomarkers Aβ42, Aβ40, Tau and P-Tau in blood and in the cerebrospinal fluid

Study summary

Alzheimer's disease (AD) is characterised by a progressive loss of memory and cognitive function. In the early stages of AD, there is a progressive accumulation of molecules: β-amyloid peptides (Aβ) in the brain. There is a link between the accumulation of Aβ peptides and the deterioration of sleep, but current knowledge does not confirmed this link. The objective of this study is to define whether there is a link between cognitive decline and sleep disorders. If a correlation is found, this could allow earlier treatment of sleep disorders in the longer term in order to slow the development of AD.

Treatment protocols in the field of Alzheimer's disease (AD) are directed towards participants at risk of developing the disease, such as those who carry at least one ε4 allele on apolipoprotein E (APOE ε4). An individual with 2 ε4 copies has a 30-55% risk of developing AD with an age of onset around 68 years and a dose effect of the allele on risk and age of onset of symptoms.

Eligibility

Primary outcome measure(s)

• Change in the Alzheimer's Disease Cooperative Study - Preclinical Alzheimer Cognitive (ADCS-PACC) scale score — From inclusion to 24 months
  The ADCS-PACC scale will be based on scores from the Mini Mental State Examination (MMSE), the Free Recall/Indicated Recall Test, the Digit Substitution Symbol Test, the Wechsler Intelligence Scale for Adults (WAIS-IV), and the 2-minute Verbal Fluency Test

Trial sites (1)

More University Hospital, Montpellier trials in France

Other trials for the same condition